Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

This study tests a combination of two new cancer drugs — sacituzumab tirumotecan (an antibody-drug conjugate) and toripalimab (an immunotherapy drug) — as a first-line treatment for people with head and neck squamous cell carcinoma (cancer of the mouth, throat, or voice box) that cannot be cured with surgery or radiation. **You may be eligible if...** - You are 18–75 years old - You have a confirmed diagnosis of locally advanced, recurrent, or metastatic head and neck squamous cell carcinoma (oropharynx, oral cavity, hypopharynx, or larynx) - This is your first time receiving systemic treatment for advanced/metastatic disease - Your cancer cannot be cured with surgery or radiation - You have adequate organ function **You may NOT be eligible if...** - You have previously received systemic treatment for advanced/metastatic head and neck cancer - You have autoimmune disease requiring systemic treatment - You are pregnant or breastfeeding - You have uncontrolled infections or certain other cancers Talk to your doctor to see if this trial is right for you.